Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat

full-text:
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat

Guidelines and Recommendations

Ensuring the integrity of clinical practice guidelines: a tool for protecting patients
Lenzer J, et al. BMJ. 2013 Sep 17;347:f5535.
Gene expression profiling and expanded immunohistochemistry tests for guiding adjuvant chemotherapy decisions in early breast cancer management: MammaPrint, Oncotype DX, IHC4 and Mammostrat (DG10), NICE, Sep 20

NICE recommends Genomic Health's Oncotype DX® test to guide chemotherapy treatment decisions for qualified early-stage invasive breast cancer patients,Yahoo, Sep 25

Medications for risk reduction of primary breast cancer in women: U.S. Preventive Services Task Force recommendation statement, USPSTF, Sep 24
Recommendations from the EGAPP Working Group: does PCA3 testing for the diagnosis and management of prostate cancer improve patient health outcomes?
Genetics in Medicine 2013 Sep 26
Tuberous sclerosis complex diagnostic criteria update: Recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
Northrup H, et al. Pediatric Neurology vol 49 iss 4 pg 243-254 2012 Oct

Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference
Krueger D, et al. Pediatric Neurology vol 49 iss 4 pg 255-265 2012 Oct

New guidelines released for diagnosis, surveillance and management of rare genetic disease called tuberous sclerosis complex, Digital Journal, Sep 23

Testing of CYP2C19 variants and platelet reactivity for guiding antiplatelet treatment, AHRQ, Sep 25